Interview: Dr. Muin J. Khoury discusses the future of public health genomics and why it matters for personalized medicine and global health

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 3, 2009, Pages 158-163

  Khoury, M J ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Global public health; International development and policy; Personalized medicine; Preventive medicine; Public health genomics

Indexed keywords

ABACAVIR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

DEVELOPMENTAL GENETICS; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; GENOMICS; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HEALTH PROMOTION; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATICS; NOTE; PATIENT SAFETY; PHARMACOGENOMICS; PUBLIC HEALTH; PUBLIC HEALTH GENOMICS;

EID: 72449208051     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692110907030158     Document Type: Note

References (52)

1. Khoury MJ, Beaty TH, Tockman MS, et al. Familial aggregation in chronic obstructive pulmonary disease: use of the loglinear model to analyze intermediate genetic and environmental factors. Genet Epidemiol 1985; 2: 155-166
2. Khoury MJ, Beaty TH, Newill GA, et al. Genetic-environmental interaction in chronic obstructive pulmonary disease. Int J Epidemiol 1986; 15: 64-71.
3. Eichelbaum M, Spannbrucker N, Dengler HJ. N-oxidation of sparteine in man and its interindividual differences. Arch Pharmacol 1975; 287: R94.
4. Kalow W, Ozdemir V, Tang BK, et al. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999; 66(5): 445-447
5. Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci 2005; 26(4): 196-201.
6. McNally R, Glasner P. Survival of the gene? 21st century visions from genomics, proteomics and the new biology. In: Glasner P, Atkinson P, Greenslade H, Eds. New Genetics, New Social Formations. London: Routledge 2007; pp. 253-278
7. Poland GA. Pharmacology, vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Ther 2007; 82(6): 623-626
8. Cohen N. Pharmacogenomics and Personalized Medicine. Totowa, NJ: Humana Press 2008.
9. Lunshof J. The new genomics: challenges for ethics. PhD Dissertation. Vrije Universiteit: Amsterdam, NL (2008). Available at: http://hdl.handle.net/ 1871/13070 [Accessed: August 5, 2009].
10. Prainsack B, Reardon J, Hindmarsh R, et al. Personal genomes: misdirected precaution. Nature 2008; 456(7218): 34-35
11. Wilke RA, Mareedu RK, Moore JH. The pathway less traveled: moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies. Curr Pharmacogenomics Person Med 2008; 6(3): 150-159
12. Ozdemir V, Suarez-Kurtz G, Stenne R, et al. Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13(1): 43-61.
13. Robitaille J. Nutrigenomics and personalized diet: what are the anticipated impacts for research on chronic diseases and public health? Curr Pharmacogenomics Person Med 2009; 7(2): 106-114
14. Caudill MA, Dellschaft N, Solis C, et al. Choline intake, plasma riboflavin, and the phosphatidylethanolamine N-methyltransferase G5465A genotype predict plasma homocysteine in folate-deplete Mexican-American men with the methylenetetrahydrofolate reductase 677TT genotype. J Nutr 2009; 139(4): 727-733
15. Singh JA, Daar AS. The 20-year African biotech plan. Nat Biotechnol 2008; 26(3): 272-274
16. Séguin B, Hardy BJ, Singer PA, et al. Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN). Nat Rev Genet 2008; 9(Suppl. 1): S5-9.
17. Hardy BJ, Séguin B, Goodsaid F, et al. The next steps for genomic medicine: challenges and opportunities for the developing world. Nat Rev Genet 2008; 9(Suppl. 1): S23-7.
18. Pang T. Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization. Curr Pharmacogenomics Person Med 2009; 7(3): 149-157
19. Khoury MJ, Bowen S, Bradley LA, et al. A decade of public health genomics in the United States: Centers for Disease Control and Prevention 1997-2007. Public Health Genomics 2008 Sep 3 [Epub ahead of print].
20. Burke W, Khoury MJ, Stewart A, Zimmern R. Bellagio working group. The Path from Genome-Based Research to Population Health: Development of an International Public Health Genomics Network. Genet Med 2006; 8: 451-458
21. Khoury MJ, the Genetics Working Group. From genes to public health: a commentary for the application of genetics in disease prevention. Am J Publ Health 1996; 86: 1717-1722
22. Beskow L, Khoury MJ, Baker T, et al. The integration of genetics into public health research, policy and practice: a blueprint for action. Community Genet 2001; 4: 2-11. (Pubitemid 32722264)
23. Khoury MJ, Gwinn M, Burke W, et al. Will genomics widen or heal the schism between medicine and public health? Am J Prev Med 2007; 33: 310-317
24. Phillips KA. Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 2008; 300: 2542-2544
25. Lai Goldman M, Faruki H. Abacavir hypersensitivity: a model system for pharmacogenomic test adoption. Genet Med 2008; 10(12): 874-878
26. Shurin SC, Nabel EG. Pharmacogenomics-ready for prime time? N Engl J Med 2008; 358(10): 1061-1063
27. Khoury MJ, Rich EC, Randhawa G, et al. Comparative effectiveness research and genomic medicine: an evolving relationship for 21st century medicine. Genet Med 2009 (in press)
28. Teutsch SM, Bradley LA, Palomaki G, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 2009; 11: 3-14.
29. EGAPP working group-recommendation statements. Genet Med 2009; 11: 15-73.
30. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10): 665-674
31. Lenfant C. Shattuck lecture: clinical research to clinical practice: lost in translation. N Engl J Med 2003; 349: 868-874 (Pubitemid 37025407)
32. Woolfe SH. The meaning of translational research and why it matters. JAMA 2008; 299(2): 211-213
33. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome is out of the bottle - will we get our wish. N Engl J Med 2008; 358(2): 105-107
34. Khoury MJ, Berg A, Coates RC, et al. The evidence dilemma in genomic medicine. Health Aff (Millwood) 2008; 2e7: 1600-1611
35. Carlson RJ. The disruptive nature of personalized medicine technologies: implications for the healthcare system. Public Health Genomics 2009; 12: 180-184
36. Secretary's Advisory Committee on Genetics, Health and Society (SACGHS). [Accessed August 5, 2009]. Available from: http://oba.od.nih.gov/sacghs/sacghs- home.html
37. Khoury MJ, McBride CA, Schully S, et al. The scientific foundation for personal genomics: recommendations from an NIH-CDC multidisciplinary workshop. Genet Med 2009 (in press).
38. Secretary's Advisory Committee on Genetics, Health and Society (SACGHS). US system of oversight of genetic testing 2008. [Accessed: August 5, 2009]. Available from: http://oba.od.nih.gov/ oba/SACGHS/reports/SACGHS-oversight- report.pdf
39. Javitt G, Katsanis S, Scott J, et al. Developin a blueprint for a genetic test registry. Public Health Genomics 2009; Published online June 29 DOI: 10.1159/000226593.
40. Khoury MJ, Feero WG, Reyes M, et al. The Genomic Applications in Practice and Prevention Network. Genet Med 2009; May 22. PMID: 19471162.
41. Little J, Higgins JP, Ioannidis JP, et al. Strengthening the Reporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 2009; 6(2): e22.
42. The Human Genome Epidemiology Network (HuGENet). [Accessed: August 5, 2009] Available from: http://www.cdc.gov/ genomics/hugenet/default.htm
43. Strengthening the reporting of observational studies in epidemiology (STROBE). [Accessed: August 5, 2009]. Available from: http://www.strobe- statement.org/
44. Haddow JE, Palomaki GE. A model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, Eds. Human genome epidemiology: scope and strategies. New York: Oxford University Press 2004; pp. 217-233.
45. Shortell SM, Weist EM, Mah-Sere KW, et al. Implementing the Institute of Medicine's recommended curriculum content in schools of public health: a baseline assessment. Am J Publ Health 2004; 94(10): 1671-1674
46. Khoury MJ, Gwinn M. Genomics, epidemiology and common complex diseases: let's not throw out the baby with the bathwater. Int J Epidemiol 2006; 35: 1363-1364 (Pubitemid 44605571)
47. Khoury MJ, Davis RL, Gwinn M, et al. Do we need genomic research for the prevention of common diseases with environmental causes? Am J Epidemiol 2005; 161: 799-805.
48. Natural History Museum. Darwin200. [Accessed: August 5, 2009] Available from: http://www.darwin200.org/index.html
49. Gardner H. Five minds for the future. Boston, MA: McGraw-Hill Ryerson Agency 2007.
50. Stokols D, Hall KL, Taylor BK, et al. The science of team science. Overview of the field and introduction to the supplement. Am J Prev Med 2008; 35(Suppl. 2): S77-S89. (Pubitemid 351932066)
51. Institute of Medicine. Genes, behaviour and the social environment: moving beyond the nature/nurture debate. Washington DC: National Academies Press 2006.
52. Yoon PW, Scheuner MT, Peterson-Oehlke KL, et al. Can family history be used as a tool for public health and preventive medicine? Genet Med 2002; 4: 304-310